381 related articles for article (PubMed ID: 28392315)
1. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients.
Castón JJ; Lacort-Peralta I; Martín-Dávila P; Loeches B; Tabares S; Temkin L; Torre-Cisneros J; Paño-Pardo JR
Int J Infect Dis; 2017 Jun; 59():118-123. PubMed ID: 28392315
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.
De la Calle C; Rodríguez O; Morata L; Marco F; Cardozo C; García-Vidal C; Río AD; Feher C; Pellicé M; Puerta-Alcalde P; Mensa J; Soriano A; Martínez JA
Int J Antimicrob Agents; 2019 Apr; 53(4):520-524. PubMed ID: 30471403
[TBL] [Abstract][Full Text] [Related]
3. Successful Treatment of Bacteremia Due to NDM-1-Producing
Hobson CA; Bonacorsi S; Fahd M; Baruchel A; Cointe A; Poey N; Jacquier H; Doit C; Monjault A; Tenaillon O; Birgy A
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530600
[No Abstract] [Full Text] [Related]
4. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae.
Sousa A; Pérez-Rodríguez MT; Soto A; Rodríguez L; Pérez-Landeiro A; Martínez-Lamas L; Nodar A; Crespo M
J Antimicrob Chemother; 2018 Nov; 73(11):3170-3175. PubMed ID: 30099490
[TBL] [Abstract][Full Text] [Related]
5. High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.
Aitken SL; Tarrand JJ; Deshpande LM; Tverdek FP; Jones AL; Shelburne SA; Prince RA; Bhatti MM; Rolston KVI; Jones RN; Castanheira M; Chemaly RF
Clin Infect Dis; 2016 Oct; 63(7):954-958. PubMed ID: 27313265
[TBL] [Abstract][Full Text] [Related]
6. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
King M; Heil E; Kuriakose S; Bias T; Huang V; El-Beyrouty C; McCoy D; Hiles J; Richards L; Gardner J; Harrington N; Biason K; Gallagher JC
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483952
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with ceftazidime/avibactam for treatment of antibiotic-resistant organisms other than Klebsiella pneumoniae.
Santevecchi BA; Smith TT; MacVane SH
Int J Antimicrob Agents; 2018 Apr; 51(4):629-635. PubMed ID: 29408227
[TBL] [Abstract][Full Text] [Related]
9. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
[TBL] [Abstract][Full Text] [Related]
10. Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant gram-negative bacteria in hematological patients: Experience in a single center.
Zhen S; Lin Q; Chen Z; Shen Y; Chen X; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Jiang E; Han M; Wang J; Feng S
J Infect Chemother; 2024 Jul; 30(7):608-615. PubMed ID: 38215820
[TBL] [Abstract][Full Text] [Related]
11. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
[TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by
Guimarães T; Nouér SA; Martins RCR; Perdigão Neto LV; Martins WMBS; Narciso Barbosa AC; Ferreira ALP; Costa SF; Gales AC
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358592
[TBL] [Abstract][Full Text] [Related]
13. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R;
Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G
BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510
[TBL] [Abstract][Full Text] [Related]
15. Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.
Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK
Int J Antimicrob Agents; 2018 Aug; 52(2):287-292. PubMed ID: 29654893
[TBL] [Abstract][Full Text] [Related]
16. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
[TBL] [Abstract][Full Text] [Related]
17. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study).
Castón JJ; Cano A; Pérez-Camacho I; Aguado JM; Carratalá J; Ramasco F; Soriano A; Pintado V; Castelo-Corral L; Sousa A; Fariñas MC; Muñoz P; Abril López De Medrano V; Sanz-Peláez Ó; Los-Arcos I; Gracia-Ahufinger I; Pérez-Nadales E; Vidal E; Doblas A; Natera C; Martínez-Martínez L; Torre-Cisneros J
J Antimicrob Chemother; 2022 Apr; 77(5):1452-1460. PubMed ID: 35187577
[TBL] [Abstract][Full Text] [Related]
18. Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.
Davido B; Fellous L; Lawrence C; Maxime V; Rottman M; Dinh A
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630191
[No Abstract] [Full Text] [Related]
19. Cure of recurring Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae septic shock episodes due to complicated soft tissue infection using a ceftazidime and avibactam-based regimen: a case report.
Parruti G; Frattari A; Polilli E; Savini V; Sciacca A; Consorte A; Cibelli DC; Agostinone A; Di Masi F; Pieri A; Cacciatore P; Di Iorio G; Fazii P; Spina T
J Med Case Rep; 2019 Jan; 13(1):20. PubMed ID: 30665450
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia.
Hakeam HA; Alsahli H; Albabtain L; Alassaf S; Al Duhailib Z; Althawadi S
Int J Infect Dis; 2021 Aug; 109():1-7. PubMed ID: 34091006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
